Shire Pharmaceuticals has strong results for the first quarter, with its attention-deficit hyperactivity disorder (ADHD) drugs driving growth, according to Pharma Times.

Net income came in at $211.3 million, up 27%, while revenues increased 19% to $972 million. Turnover was driven by the ADHD drug Vyvanse (lisdexamfetamine dimesylate), which grew 31% to $202.3 million, and Adderall XR (mixed amphetamine salts) brought in $111.2 million, up 21%. Another ADHD drug, Intuniv (guanfacine), had sales of $41.9 million.

Shire rare diseases portfolio also fared particularly well, with Replagal (agalsidase alfa) for Fabry disease increased 55% to $105.4 million. Vpriv (velaglucerase alfa) for Gaucher's disease, brought in $59 million, up 917. The Hunter Syndrome therapy Elaprase (idursulfase) rose 3% to $103.5 million.

As for Shire's other products, Pentasa (mesalamine) climbed 11% to $64.5 million, and the firm’s newer ulcerative colitis drug Lialda/Mezavant brought in $87.1 million, up 37%.

The company also revealed positive phase II data looking at Vyvanse as a potential adjunctive treatment in for the negative symptoms of schizophrenia. Plans for a study in binge eating disorder as well as the continuing phase III program looking at Vyvanse for major depressive disorder may be underway as well.